-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。12ヶ月目標株価を4ドル引き上げ、75ドルとします。これは、2026年のEPS予想の18倍に相当し、過去5年間の平均株価収益率（13倍）を上回る水準です。2026年のEPS予想は3.97ドルから4.17ドルに、2027年のEPS予想は4.28ドルから4.55ドルにそれぞれ引き上げます。売上高と利益が予想を上回った第1四半期決算を受け、当社は引き続き「買い」の投資判断を維持します。CAKEは、体験型ダイニングに注力することで、旗艦店であるチーズケーキファクトリーの既存店売上高成長率（第1四半期は1.6%増）を支え、同時に価格上昇率（3.3%増）は同業他社を上回っています。さらに、ファストカジュアルブランドのフラワーチャイルドのような新しいコンセプトが、経営陣の予想（一桁台半ば）を上回る前年比10%増という既存店売上高成長率を加速させています。牛肉や魚介類のコストが継続的に上昇しているにもかかわらず、営業利益率5.8%は安定しており、従業員の定着率の高さによる人件費の削減がそれを相殺しています。これは、レストラン業界の競合他社が利益率の低下に苦しんでいる時期に達成されたものであり、心強い限りです。総合的に見て、CAKEの2026年の財務目標である売上高39億1000万ドル、純利益率5%には、上振れ余地があると見ています。
Related Articles
Research
Research Alert: CFRA Maintains Buy Rating On Shares Of Tyler Technologies Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to $394 from $402, on a forward P/E of 31x our 2026 EPS projection of $12.71, below its three-year average but above peers on the resilience of the business. We increase our 2026 EPS projection to $12.71 from $12.57 and lift our 2027 EPS forecast to $14.28 from $14.19. TYL reported Q1 2026 revenue of $613.5M, up 8.6% Y/Y, led by exception SaaS revenue acceleration of 23.5% to $222.4M. Transaction-based revenues grew 6.4% to $207.4M. Customers are committing to cloud deployments as modernization efforts are underway and AI use skews toward greater cloud use. We expect this trend to sustain SaaS momentum, increasing our confidence in 20%-plus SaaS growth in the near to medium term. Non-GAAP operating margin expanded 40 bps to 27.2%, while adjusted EBITDA increased 9.3% to $177.3M, benefiting from favorable revenue mix toward higher-margin SaaS and transaction revenues, cloud efficiency gains, and disciplined expense management.
$TYL
Research
Research Alert: CFRA Maintains Hold Opinion On Shares Of American Water Works Company, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target by $1 to $139, 21.2x our 2027 EPS estimate, a discount to AWK's five-year forward average of 25.1x. We keep our 2026 EPS view at $6.09 and lift 2027 EPS by $0.08 to $6.58. The Q1 EPS miss (-7.4%) is the latest in a series of misses, with seven in the last nine quarters coming in below expectations at an average of -3.1%. Our Hold opinion reflects our moderately balanced view of risks and rewards, particularly around the WTRG merger, though regulatory approval in Kentucky provides some relief to transaction uncertainty. We think higher for longer interest rates will pressure valuations. In the FOMC's most recent meeting, three regional presidents backed the hold on rates but rejected the statement's easing bias, which we interpret as a signal that the Fed's next move may not be a rate cut. We think the acceleration of closing expectations (June 30, 2026 vs. August 2026) for the Nexus Water Group Systems will boost 2026 sales, as we now anticipate 7% Y/Y growth.
$AWK
Research
Research Alert: CFRA Maintains Buy Rating On Shares Of Labcorp Holdings Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $300 from $325, 16.6x our 2026 EPS estimate, a premium to LH's three-year historical forward average of 15.3x, supported by our favorable view for health care services, including healthy lab testing volume growth within an environment of high medical utilization, as well as attractive growth prospects given new therapies and aging demographics, in our opinion. We raise our 2026 EPS estimate to $18.03 from $17.90 and raise our 2027 estimate to $19.32 from $19.15. Q1 2026 acquisitions were $202 million, including operations from Crouse Health's Laboratory Alliance of Central New York, while management expressed confidence in the upcoming deal pipeline during the Q1 earnings conference call. Acquisitions totaled $582 million during 2025. LH anticipates a 30 bps headwind for diagnostics volumes in 2026 due to the recent expiration of ACA enhanced premium tax credits, which we expect to cause a meaningful drop in ACA exchange insurance coverage.
$LH